Mercaptamine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), HAS (France) and NYE METODER (Norway), among others, recommended or restricted mercaptamine, while CIPM (Spain) and TLV (Sweden) did not recommend it.
Assessment has run over 10.2 years, from 23 Sep 2015 at HAS (France) to 10 Nov 2025 at SMC (Scotland).
AWMSG (Wales) changed its position: not recommended on 25 May 2017, recommended by 12 May 2022, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for mercaptamine, 1 submission was never made — an outcome set by the company rather than the assessor.
3 distinct indication wordings are recorded for mercaptamine by the agencies that label one in English (AWMSG and SMC).
HAS (France) was first to assess mercaptamine, on 23 Sep 2015; NYE METODER (Norway) did not open a file until 19 Jun 2022 — a wide spread of 6.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
7 of the 7 agencies here assessed mercaptamine more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for mercaptamine.
The full ledger for mercaptamine reads 10 recommended, 5 not recommended, 1 non-submission and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 19 Jun 2022 | Behandling av avleiringer av cystinkrystaller i hornhinnen hos voksne og barn >2 år med cystinose. (Øyedråper) | introduced | source |
| CIPM (Spain) | 5 May 2022 | Indicación terapéutica autorizada: Cystadrops está indicado para el tratamiento de los depósitos de cristales de cistina… | not financed by the SNS · art. 92 d, e | source |
| SMC (Scotland) | 8 Feb 2021 | Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis. | not recommended | source |
| AOTMIT (Poland) | 5 Feb 2019 | Cystadrops reimbursement recommendation | recommended conditionally | source |
| AWMSG (Wales) | 25 May 2017 | Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis | not endorsed (non-submission) | source |
12 further decisions for mercaptamine, across 7 agencies, are not shown here. They include the most recent record on file, 10 Nov 2025 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- pegcetacoplan — same ATC class S01X — Ophthalmologicals
- ciclosporin — same ATC class S01X — Ophthalmologicals
- voretigene neparvovec — same ATC class S01X — Ophthalmologicals
- ocriplasmin — same ATC class S01X — Ophthalmologicals
- cenegermin — same ATC class S01X — Ophthalmologicals
- iptacopan — also decided by SMC in 2025Q4
Coverage: 17 decisions for mercaptamine from 7 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class S01X — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.